



29 January 2019

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD)) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 31 December 2018, on Wednesday 30 January 2019.

Investors are invited to join a conference call with Managing Director and CEO, Richard Carreon at **9.00am AEDT on Wednesday 30 January 2019.**

To pre-register please follow this link:

<https://services.choruscall.com.au/diamondpass/impedimed-891203-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call.

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

For personal use only